… target for tumour radiosensitisation. Here, … HIF-1 blockade with radiotherapy. In doing so,
we describe clinical scenarios in which HIF-1 inhibition might optimise tumour radiosensitivity. …

… Although this study focused on the involvement of HIF-1 in determining tumor radiosensitivity,
the findings may apply to other treatment modalities. As mentioned above, reoxygenation …

… the tumor vasculature. The impact that HIF-1 activation has on overall tumor radiosensitivity,
… We reveal here that HIF-1 plays an important role in determining tumor radioresponsiveness …

… , which is accompanied by enhanced radiosensitivity. Colen and colleagues suggested that
… , it does not predict the radiosensitivity of tumors in an in vivo tumor model (25). However, …

… not affect tumor growth [37,47]. Based on our findings, we suggest that dual HIF-1α/HIF-2α
inhibitors are potentially clinically relevant enhancers of tumor radiosensitivity, but that HIF-1α …

… of HIF in cancer tissues suggests that it plays roles in cancer … We used the keywords, HIF,
cancer, cell to search for HIF-1 … by the radiation sensitivity status of non-small-cell lung cancers. …

… by repression of hypoxia-inducible factor HIF1 or tumour protein TP53. … of vorinostat in prostate
cancer cell lines grown under … cancer cell lines with different intrinsic radiosensitivity were …

… treated with radiotherapy can no longer only be based solely on the physico-chemical
mechanism by which oxygen increases the radiation sensitivity of hypoxic cells. In solid …

… HIF-1α affects chemo-/radiosensitivity via regulation of genes related to metabolic pathways.
For example, Meijer et al Citation28 showed that HIF-1α … chemo-/radiosensitivity in tumors. …

… Although cells are more radiosensitive at the late G 1 and early S phases than at the late
S phase, cell cycle arrest/retardation at any checkpoint is considered to enhance the …